PALVELLA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | – | $-1.52 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-1.20 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | – | $-1.03 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.86 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $-0.74 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 18, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 10, 2023 | Before market open | $1.94M | $-0.18 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 29, 2023 | Before market open | – | – | – |
Press releases
Announcements Palvella Therapeutics filed with the SEC
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare diseases Q2 2026 Financial Results & Corporate Update August 4, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-PALVELLA THERAPEUTICS CORPORATE PRESENTATION - JULY 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON MAY 20, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON MAY 15, 2026
Other events · EX-99.1 to Form 8-K
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare diseases Q1 2026 Financial Results & Corporate Update May 7, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-PALVELLA THERAPEUTICS CORPORATE PRESENTATION - APRIL 2026
Other events · EX-99.1 to Form 8-K
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare diseases Full Year 2025 Financial Results & Corporate Update March 31, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
CORPORATE PRESENTATION ON PHASE 3 SELVA STUDY OF QTORIN DATED FEBRUARY 24, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON FEBRUARY 24, 2026
Other events · EX-99.1 to Form 8-K
PALVELLA THERAPEUTICS CORPORATE PRESENTATION - JANUARY 2026
Other events · EX-99.1 to Form 8-K
PALVELLA THERAPEUTICS CORPORATE PRESENTATION - JANUARY 2026
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Palvella Therapeutics Announces Positive Topline
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare skin diseases Q3 2025 Financial Results & Corporate Update November 11, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Palvella Therapeutics Announces New QTORIN™
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare genetic skin diseases Q2 2025 Financial Results & Corporate Update August 14, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare genetic skin diseases Q1 2025 Financial Results & Corporate Update May 15, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-disease therapies for patients with rare genetic skin diseases Full Year 2024 Financial Results & Corporate Update March 31, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PALVELLA MANAGEMENT ’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
For the Quarterly Period Ended September 30, 2024
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.3 to Form 8-K
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.3 to Form 8-K
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Results of operations · Other events · EX-99.1 to Form 8-K
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Agreement terminated · Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K